Related Experiment Video
Updated: Jan 8, 2026

Environmental Modulations of the Number of Midbrain Dopamine Neurons in Adult Mice
Published on: January 20, 2015
Do calcium antagonists affect platelets?
1Department of Clinical Pharmacology, St. Mary's Hospital Medical School, London, U.K.
Insights
Calcium antagonists show potential in treating cardiovascular diseases by inhibiting platelet activation. However, their clinical effectiveness and mechanism require further investigation for practical patient benefit.
Area of Science:
- Cardiovascular Pharmacology
- Hematology
Background:
- Inappropriate platelet activation contributes to cardiovascular disorders like ischemic heart disease and hypertension.
- Calcium antagonists are widely used for these conditions.
Purpose of the Study:
- To explore the potential anti-platelet effects of calcium antagonists.
- To investigate the clinical relevance of these effects in cardiovascular therapy.
Main Methods:
- In vitro and ex vivo studies assessing platelet activation in the presence of calcium antagonists.
- Review of existing literature on drug concentrations, receptor binding, and clinical outcomes.
Main Results:
- Calcium antagonists consistently inhibit platelet activation in vitro.
- Inhibition is less consistent ex vivo.
- Clinical drug concentrations may be insufficient for significant anti-platelet effects.
Conclusions:
- While calcium antagonists demonstrate in vitro anti-platelet activity, their clinical significance remains uncertain.
- Further research is needed to clarify the mechanism of action and therapeutic value in patients.
Abstract:
Inappropriate platelet activation is thought to have a pathophysiological role in several cardiovascular disorders, including ischaemic heart disease and hypertension. Calcium antagonists are increasingly used in the therapy of these diseases. An inhibitory effect on platelet activation would clearly be a useful component of their therapeutic effect. Since a raised intracellular calcium concentration is crucial for platelet activation, and much of the calcium enters from the extracellular medium, such an effect might be anticipated. In fact, calcium antagonists consistently inhibit platelet activation in vitro, and somewhat less consistently ex vivo. However, many unanswered questions remain. Clinically attained drug concentrations in plasma may be too low to be effective, there appear to be no calcium antagonist receptors on the platelet, and the mechanism of action of the drugs is unclear. More importantly, it is not known whether an anti-platelet effect, if it occurs, is of practical rather than theoretical, value to the patient. These problems will need much more investigation.
Related Concept Videos
09:21Phenotypic Profiling of Human Stem Cell-Derived Midbrain Dopaminergic Neurons
10:54Reliable Identification of Living Dopaminergic Neurons in Midbrain Cultures Using RNA Sequencing and TH-promoter-driven eGFP Expression
08:45Isolation, Culture and Long-Term Maintenance of Primary Mesencephalic Dopaminergic Neurons From Embryonic Rodent Brains
09:35Environmental Modulations of the Number of Midbrain Dopamine Neurons in Adult Mice
11:58Primary Culture of Mouse Dopaminergic Neurons
09:54Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

